Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[HBME-1 immunostaining in thyroid pathology].

V Rigau1, B Martel, C Evrard

  • 1Laboratoire d'Anatomie Pathologique, Centre Hospitalo-Universitaire, Caen.

Annales De Pathologie
|February 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Apilimod in oncology: From non-malignant origins to emerging anti-cancer potential.

European journal of pharmacology·2026
Same author

Threshold cost of delivering preventive treatment for household contacts of people with multidrug-resistant TB.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study).

ESMO gastrointestinal oncology·2026
Same author

Gene expression profiling in a retrospective real-world cohort of breast cancer brain metastases and paired primary tumors identifies biological changes with potential therapeutic implications.

ESMO open·2025
Same author

Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.

British journal of haematology·2024
Same author

Update on gene fusions and the emerging clinicopathological landscape of peritoneal and pleural mesotheliomas and other neoplasms.

ESMO open·2024
Same journal

[Case no. 2. Pseudotumoral pulmonary IgG4 disease].

Annales de pathologie·2026
Same journal

[Diffuse large B-cell lymphoma-NOS , high-grade B-cell lymphomas and Burkitt lymphoma: Updates].

Annales de pathologie·2026
Same journal

[Ironing out the diagnosis].

Annales de pathologie·2026
Same journal

[Ecological transformation and quality of surgical pathological analysis: Not such an insoluble equation].

Annales de pathologie·2026
Same journal

[Cerebrospinal fluid in the context of headaches with decreased visual acuity].

Annales de pathologie·2026
Same journal

[Facial granulomatous lesion in a traveler].

Annales de pathologie·2026
See all related articles

The HBME-1 antibody test can help distinguish benign thyroid nodules from malignant thyroid carcinomas. This immunohistochemical analysis shows high accuracy in identifying papillary thyroid cancers.

Area of Science:

  • Endocrinology
  • Oncology
  • Pathology

Context:

  • Thyroid carcinomas present a diagnostic challenge, necessitating accurate differentiation from benign lesions.
  • Immunohistochemical markers are crucial for refining thyroid cancer diagnosis.

Purpose:

  • To assess the diagnostic utility of HBME-1 immunohistochemistry in differentiating benign thyroid lesions from various types of thyroid carcinomas.
  • To evaluate the sensitivity and specificity of HBME-1 in identifying different thyroid malignancy subtypes.

Summary:

  • HBME-1 immunohistochemical analysis was performed on 50 benign and 87 malignant thyroid lesions.
  • All papillary carcinomas (100%) and a significant proportion of follicular carcinomas (70%) were HBME-1 positive.
  • Focal and weak positivity was observed in some atypical follicular adenomas and goiters, while micronests and specific variants like tall-cell papillary carcinoma showed distinct staining patterns.

Related Experiment Videos

Impact:

  • HBME-1 immunostaining supports the diagnosis of papillary thyroid carcinoma, including its follicular variant and micropapillary subtypes.
  • This marker may serve as a valuable adjunct in the accurate diagnosis of thyroid malignancy, improving patient management.